Acadian Asset Management’s VistaGen Therapeutics VTGN Stock Holding History

Acadian Asset Management’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$336K	Buy	+589,663	New	+$358K	﹤0.01%	1454
2024 Q2	–	Sell	-32,291	Closed	-$169K	–	1911
2024 Q1	$169K	Buy	+32,291	New	+$155K	﹤0.01%	1211
2022 Q4	–	Sell	-6,214	Closed	-$28K	–	1929
2022 Q3	$28K	Buy	+6,214	New	+$61.6K	﹤0.01%	1568
2018 Q3	–	Sell	-533	Closed	-$22K	–	1807
2018 Q2	$22K	Buy	+533	New	+$18.5K	﹤0.01%	1518

Other funds holding VTGN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return

Acadian Asset Management's VTGN Position: Q1 2026 in Review

Acadian Asset Management opened a new position in VistaGen Therapeutics (VTGN) in Q1 2026: 589,663 shares worth $336K. The stake represents ﹤0.01% of the portfolio and ranks #1454 among its holdings. This is a return to the name: Acadian Asset Management previously reported a position in VTGN as recently as Q1 2024.

Acadian Asset Management first reported a position in VTGN in Q2 2018 and has held it in 4 quarters since. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

Acadian Asset Management held 589,663 shares of VistaGen Therapeutics worth $336K as of Q1 2026.
VistaGen Therapeutics was a new Acadian Asset Management position in Q1 2026.
VistaGen Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #1454 holding.
Acadian Asset Management first reported a position in VistaGen Therapeutics in Q2 2018 and has held it in 4 quarters since.
56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.